Patient and transplantation details
Characteristics . | . |
|---|---|
| Sex, n, M/F | 46/19 |
| Median age at transplantation, y (range) | 45.6 (18.9-60.4) |
| Histology at diagnosis, n | |
| Low-grade NHL* | 28 |
| Mantle cell lymphoma | 5 |
| High-grade NHL | 8 |
| CLL/PLL | 13 |
| PTCL | 5 |
| Hodgkin lymphoma | 5 |
| Risk group at transplantation, n† | |
| Good risk | 13 |
| Intermediate risk | 17 |
| Poor risk | 27 |
| Unknown | 8 |
| Prior chemotherapy regimes, n (range) | 2 (1-6) |
| Transplantation characteristics, n | |
| HLA-identical related donor | 52 |
| 1 Ag mismatch related donor | 5 |
| Matched unrelated donor | 8 |
| PBSCs | 56 |
| BM | 8 |
| PBSCs and BM | 1 |
| CMV serostatus, n | |
| Recipient negative/donor negative | 26 |
| Recipient negative/donor positive | 11 |
| Recipient positive | 28 |
Characteristics . | . |
|---|---|
| Sex, n, M/F | 46/19 |
| Median age at transplantation, y (range) | 45.6 (18.9-60.4) |
| Histology at diagnosis, n | |
| Low-grade NHL* | 28 |
| Mantle cell lymphoma | 5 |
| High-grade NHL | 8 |
| CLL/PLL | 13 |
| PTCL | 5 |
| Hodgkin lymphoma | 5 |
| Risk group at transplantation, n† | |
| Good risk | 13 |
| Intermediate risk | 17 |
| Poor risk | 27 |
| Unknown | 8 |
| Prior chemotherapy regimes, n (range) | 2 (1-6) |
| Transplantation characteristics, n | |
| HLA-identical related donor | 52 |
| 1 Ag mismatch related donor | 5 |
| Matched unrelated donor | 8 |
| PBSCs | 56 |
| BM | 8 |
| PBSCs and BM | 1 |
| CMV serostatus, n | |
| Recipient negative/donor negative | 26 |
| Recipient negative/donor positive | 11 |
| Recipient positive | 28 |
CLL/PLL indicates chronic lymphocytic leukemia/prolymphocytic leukemia; PTCL, peripheral T-cell lymphoma; CR1, first complete remission; CR2, second complete remission; PR1, first partial remission; Ag, antigen; PBSCs, peripheral blood stem cells; BM, bone marrow; and CMV, cytomegalovirus.
Low-grade and transformed low-grade NHL.
Good risk indicates CR1, CR2; intermediate risk, CR > 2, PR1; and poor risk, PR > 1, refractory relapse, or primary progressive disease.